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The Impact of Penicillinase on Cefamandole Treatment and Prophylaxis of
Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus
Yok-Ai Que, Jose´-M. Entenza, Patrick Francioli, Division of Infectious Diseases, Department of Internal Medicine,
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerlandand Philippe Moreillon
b-lactams active against methicillin-resistant Staphylococcus aureus (MRSA) must resist penicil-
linase hydrolysis and bind penicillin-binding protein 2A (PBP 2A). Cefamandole might share these
properties. When tested against 2 isogenic pairs of MRSA that produced or did not produce penicil-
linase, MICs of cefamandole (8–32 mg/L) were not affected by penicillinase, and cefamandole had
a ⁄40 times greater PBP 2A affinity than did methicillin. In rats, constant serum levels of 100 mg/
L cefamandole successfully treated experimental endocarditis due to penicillinase-negative isolates
but failed against penicillinase-producing organisms. This suggested that penicillinase produced in
infected vegetations might hydrolyze the drug. Indeed, cefamandole was slowly degraded by penicil-
linase in vitro. Moreover, its efficacy was restored by combination with sulbactam in vivo. Cefaman-
dole also uniformly prevented MRSA endocarditis in prophylaxis experiments, a setting in which
bacteria were not yet clustered in the vegetations. Thus, while cefamandole treatment was limited
by penicillinase, the drug was still successful for prophylaxis of experimental MRSA endocarditis.
Most methicillin-resistant staphylococci produce both peni- therapy with vancomycin in both rat and rabbit experiments.
Against penicillinase-producing isolates, however, successfulcillinase and a new, low-affinity penicillin-binding protein
called PBP 2A [1]. This additional membrane polypeptide con- treatment required the addition of critical amounts of penicil-
linase inhibitors, such as sulbactam or clavulanate, to protectfers intrinsic resistance to virtually all b-lactam antibiotics and
is thought to ensure peptidoglycan assembly when normal the drugs from penicillinase-induced hydrolysis [5, 9]. Thus,
anti-MRSA b-lactams should combine the abilities both to bindstaphylococcal PBPs are blocked by b-lactam drugs. Indirect
evidence for this hypothesis was provided both by cell wall to PBP 2A and to resist penicillinase-mediated degradation if
they were to be considered for clinical use.analysis of methicillin-susceptible and -resistant staphylococci
[2] and by site-specific mutation of the PBP 2A active serine An experimental carbapenem (L-695,256) sharing these
properties has recently demonstrated good in vivo activity inresidue [3]. These experiments suggested that PBP 2A was a
transpeptidase and thus resembled other bacterial PBPs. More- the rabbit model of MRSA endocarditis [7]. However, such
molecules are not yet available for treatment in humans. Amongover, when methicillin-resistant staphylococci were grown in
the presence of high methicillin concentrations, they switched nonexperimental b-lactams, on the other hand, the cephalospo-
rin cefamandole might possess these characteristics. Cefaman-from the synthesis of a normal peptidoglycan (in the absence
of the drug) to the production of a poorly cross-linked and dole has a good penicillinase stability and an excellent activity
against methicillin-susceptible staphylococci [10]. In addition,structurally distinct cell wall (in the presence of methicillin)
that was likely to result from the uninhibited activity of PBP cefamandole has relatively low MIC for MRSA and was re-
ported to be effective in the treatment of MRSA soft tissue2A [4]. Therefore, it is not astonishing that certain b-lactams
with relatively good PBP 2A affinity have a demonstrable activ- infections in humans [11, 12]. In the present experiments, we
further investigated the efficacy of cefamandole against a seriesity against methicillin-resistant staphylococci [5–9].
The potential usefulness of such compounds was first ob- of isogenic pairs of MRSA that produced or did not produce
penicillinase. Investigations included in vitro determinations ofserved with ‘‘old-fashioned’’ molecules such as penicillin G,
ampicillin, and amoxicillin [5–9]. These molecules appeared drug susceptibility and PBP 2A affinity as well as in vivo
therapeutic and prophylactic studies in the rat model of experi-to be effective in the treatment of experimental endocarditis
due to penicillinase-negative isolates of methicillin-resistant mental endocarditis.
Staphylococcus aureus (MRSA) and were equivalent to control
Materials and Methods
Microorganisms and growth conditions. The bacterial isolatesReceived 24 January 1997; revised 21 July 1997.
Grant support: Eli Lilly, Geneva. used in this study are described in table 1. COL and P8 were 2
Reprints or correspondence: Dr. Philippe Moreillon, Division of Infectious clinical isolates of MRSA expressing, respectively, homogeneous
Diseases, Dept. of Internal Medicine, Centre Hospitalier Universitaire Vaudois,
and heterogeneous resistance to methicillin [5, 13]. COL was peni-1011 Lausanne, Switzerland.
cillinase-negative, while P8 was penicillinase-positive. A penicil-
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linase-producing transformant of COL was obtained by DNAq 1998 by The University of Chicago. All rights reserved.
0022–1899/98/7701–0021$02.00 transformation with the penicillinase-encoding plasmid pI524. A
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Table 1. Phenotypes of methicillin resistance and penicillinase (Bla) the plates against the concentrations of antibiotic in the plates. In
production and MICs of various antibiotics for test organisms. vitro time-kill curves were made as described [6].
Titration of PBP 2A. The presence of PBP 2A was determined
Homogeneous Heterogeneous in membrane fractions of bacterial lysates of the penicillinase-
resistant resistant negative COL0, as previously described [13]. In brief, 75-mL por-
tions of membrane suspensions containing 4 mg/mL protein were
Antibiotic MSSA Bla0* COL0 COL/ P80 P8/
incubated for 10 min at 377C with 25 mL of a 1:10 (wt/wt) solution
of [3H]penicillin (77 mCi/mg) and cold penicillin to a final concen-Methicillin 1 128 128 64 64
tration of 2.5 mg/L [3H]penicillin/mL of membrane suspension.Flucloxacillin 0.5 64 64 32 32
The reaction was stopped by the addition of a 100-fold excess ofPenicillin G 0.004 8 128 4 128
Amoxicillin 0.125 16 128 8 128 cold penicillin, and the membranes were dissolved in the detergent
Amoxi-Clav† 0.125 16 64 8 8 sarkosyl. The membrane proteins were separated by SDS-PAGE,
Cefuroxime 1 128 128 32 32 and the [3H]penicillin-labeled PBPs were visualized by fluorogra-
Cefamandole 0.5 16 32 2 4 phy [5]. The binding affinities of methicillin, cefamandole, and
Sulbactam 128 128 128 128 128 amoxicillin for PBP 2A were assessed by measuring their ability
Cefam-Sul‡ 0.5 16 16 2 2
to compete for the binding of [3H]penicillin to PBPs [5]. Aliquots
Vancomycin 2 2 2 2 2
of membrane suspensions were distributed into series of tubes
containing 2-fold serial dilutions of the competitor and incubated* Methicillin-susceptible S. aureus (MSSA) strain RN 2677 used as control.
† Amoxicillin and clavulanate combined in 5/1 (wt/wt) ratio. for 10 min at 377C before [3H]penicillin was added. The tubes were
‡ For MIC determination, cefamandole was combined with constant concen- incubated for another 10 min at 377C and processed as described.
tration of 4 mg/L sulbactam. Table indicates MICs of cefamandole. Intensities of the PBP 2A bands were quantified by densitometry
by use of the ImageQuant version 3.3 software (Molecular Dynam-
ics, Sunnyvale, CA). Binding affinities of the competing drugs
were derived from densitometry quantification and expressed as
penicillinase-negative derivative of P8 was obtained by tempera- the drug concentration inhibiting binding of [3H]penicillin by 50%
ture-induced loss of the penicillinase-encoding plasmid during and 90% (IC50 and IC90).
growth at 437C [5]. For the sake of clarity, these pairs of bacteria Penicillinase stability of antibiotics in vitro. The ability of
are referred to as COL0/COL/ and P80/P8/ (for penicillinase- cefamandole, methicillin, and amoxicillin to resist penicillinase-
negative and penicillinase-positive isolates, respectively). RN2677 induced degradation was measured in broth cultures by use of a
is a methicillin-susceptible laboratory isolate of S. aureus used as described bioassay [15]. Both pairs of MRSA P8 and COL, produc-
a control in in vitro experiments [5, 13]. Unless otherwise stated, ing or not producing penicillinase, were used in this test.
bacteria were grown at 357C in tryptic soy broth (TSB; Difco, Production of endocarditis and infusion pump installation.
Detroit) with aeration or on tryptic soy agar (TSA; Difco) supple- Catheter-induced sterile aortic vegetations were produced in rats
mented with 2% NaCl. Plates were routinely supplemented with as previously described [16]. At the same time, an intravenous (iv)
penicillinase (Bacto-Penase concentrate; Difco; 2000 U/mL final catheter was inserted via the jugular vein into the superior vena
concentration) to avoid antibiotic carryover. Stocks were kept at cava and connected to a programmable infusion pump (Pump 44;0707C in TSB supplemented with 10% (vol/vol) glycerol. Harvard Apparatus, South Natick, MA) to deliver the antibiotics
Antibiotics and chemicals. Cefamandole and vancomycin [6]. The pump was set to deliver a volume of 0.2 mL of saline/h
were obtained from Eli Lilly (Indianapolis); cefuroxime was ob- to keep the catheter open until the onset of therapy. No iv catheters
tained from Glaxo Pharmaceuticals (London); penicillin G was were placed in the control animals.
obtained from Hoechst-Pharma (Zurich); [3H]penicillin (9 mCi/ Bacterial endocarditis was induced 24 h after catheterization by
mL; 117 mg/L) was provided by Merck Sharp & Dohme (Rahway, iv challenge of the animals with 0.5 mL of saline containing 105
NJ); sulbactam was obtained from Pfizer (Orsay, France); and cfu of either of the test organisms. This inoculum was 10 times
methicillin, flucloxacillin, amoxicillin, and amoxicillin-clavulanate larger than the minimum inoculum producing endocarditis in 90%
were obtained from Beecham Research Laboratories (Brockham of the untreated rats.
Park, UK). Treatment of experimental endocarditis. Antibiotic therapy
Antibiotic susceptibility, population analysis profile, and in vitro was started 12 h after bacterial challenge and lasted for 3 days.
time-kill curves. MICs of antibiotics were determined by a pre- The drugs were administrated at changing flow rates with the pump
viously described broth macrodilution method [14] in Mueller- to produce either of the following kinetics in the serum of rats:
Hinton broth (Difco) supplemented with 2% NaCl; 105 cfu/mL was simulation of sequential iv administration of 3 g of cefamandole
used as inoculum. The MIC was defined as the lowest antibiotic given 4 times a day to humans [17, 18]; continuous iv infusion of
concentration inhibiting visible bacterial growth after 24 h of incu- cefamandole producing constant serum concentrations of 100 mg/
bation at 357C. The phenotypic expression of b-lactam resistance L (this concentration was chosen because it inhibited at least 90%
was determined by spreading large bacterial inocula (109 cfu) as of PBP 2A in vitro; see Results); and simulation of sequential iv
well as smaller inocula (106, 105, and 103 cfu) onto TSA plates administration of 1 g of vancomycin given twice daily to humans
containing 2% NaCl and 2-fold serial dilutions of antibiotics [5]. [6]. This required total amounts of antibiotics of, respectively,
The numbers of colonies growing on the plates were enumerated cefamandole at 250 mg/kg of body weight/24 h (for the two cefa-
after 48 h of incubation at 357C. Population analysis profile curves mandole regimens) and vancomycin at 23.2 mg/kg of body weight/
12 h. In certain experiments, cefamandole was combined withwere generated by plotting the numbers of colonies growing on
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sulbactam, which was administered via a separate pump and which Kruskal-Wallis one-way analysis of variance on ranks with subse-
quent pairwise testing by the Dunn’s method. Overall, differencessimulated in rats the human pharmacokinetics produced by admin-
istration of 1 g of the drug given 4 times a day [9]. This required were considered significant at P£ .05 by use of two-tailed signifi-
cance levels.the administration of sulbactam at 50 mg/kg of body weight/6 h.
Prophylaxis of experimental endocarditis. Antibiotic prophy-
laxis was started 1 h before bacterial challenge and lasted for 1
day [19]. Kinetics of antibiotics in the serum of rats were as
Resultsfollows: simulation of sequential iv administration of 1 g of
flucloxacillin given 4 times a day to humans [20], simulation of
Antibiotic susceptibility, population analysis profile, andsequential iv administration of 3 g of cefamandole given 4 times
time-kill curves. Table 1 shows the MICs of various antibiot-a day to humans (as above), continuous iv infusion of cefamandole
producing constant serum levels of 100 mg/L (as above), or simula- ics for the 4 test organisms. All of the organisms were highly
tion of sequential iv administration of 1 g of vancomycin given resistant to methicillin and flucloxacillin. Amoxicillin had a
twice daily to humans (as above). Total amount of drug given to relatively good activity against the penicillinase-negative deriv-
the animals was 42.3 mg of flucloxacillin/6 h. Amounts of drug atives but required the addition of clavulanate to be active
for the other regimens were as described above. against the penicillinase-producing organisms. In contrast, the
Antibiotic concentrations in serum. Concentrations of antibi- MIC of cefamandole remained essentially unaffected by peni-
otic in serum were determined in groups of 4–9 uninfected or
cillinase production or by combination with sulbactam.
infected rats. Serum levels in infected animals came from internal
Figure 1 shows the population analysis profile of the homo-controls for adequate drug delivery in therapeutic experiments.
geneously resistant COL0 and its penicillinase-producing de-Blood was drawn by puncturing the periorbital sinuses of the ani-
rivative COL/. As in the MIC determinations, amoxicillin wasmals at several time points during and after antibiotic administra-
relatively effective against the penicillinase-negative versiontion. Antibiotic concentrations were determined by an agar diffu-
sion assay with antibiotic medium 1 (Difco) and Bacillus subtilis of the organisms but lost its activity in the presence of penicil-
ATCC 6633 as the indicator organism for cefamandole, flucloxa- linase. In contrast, cefamandole was active against both penicil-
cillin, and vancomycin and Acinetobacter calcoaceticus as the linase-negative and penicillinase-positive isolates. The same
indicator organism for sulbactam. The diluent was pooled rat se- observation was made with the penicillinase-negative and peni-
rum. The limits of detection of the assays were 0.3 mg/L for cillinase-positive versions of the heterogeneously resistant P8.
cefamandole, 0.3 mg/L for flucloxacillin, 0.6 mg/L for vancomy- Moreover, when an additional panel of 10 unrelated clinical
cin, and 3.12 mg/L for sulbactam. The linearity of the standard
isolates of penicillinase-producing MRSA were tested, none of
curves was assessed by a regression coefficient of ⁄0.995, and
them grew on agar plates containing 32 mg/L cefamandole,intraplate and interplate variations were £10%.
while they grew on plates containing up to 1000 mg/L methicil-Evaluation of infection. In therapeutic experiments, the control
lin, flucloxacillin, or amoxicillin (data not shown). This showsrats were sacrificed at the time of treatment onset (i.e., 12 h after
that the relatively good anti-MRSA activity of cefamandoleinoculation) to measure both the frequency and the severity of
valvular infection at the start of therapy. Treated rats were sacri- could be extended beyond the limit of the test bacteria used in
ficed 18–24 h after the last antibiotic dose, at least 12 h after the the present experiments.
trough level of drug in serum was reached. At that time, no residual Time-kill experiments were done with antibiotic concentra-
antibiotic could be detected in the blood. In prophylaxis experi- tions readily achieved in human serum. Cefamandole was bac-
ments, control rats were killed 24 h after bacterial challenge, tericidal against all 4 test organisms, as shown by viability
whereas rats receiving prophylaxis were killed after 3 days (i.e., losses of ⁄3 log10 cfu/mL after 24 h of exposure to drug at2 days after the end of antibiotic administration). The valvular
100 mg/L. Amoxicillin (40 mg/L) was bactericidal only against
vegetations were sterilely dissected, weighed, homogenized in 1
the penicillinase-negative derivatives and required the additionmL of saline, and serially diluted before being spread on penicil-
of clavulanate to kill penicillinase-producing isolates. In con-linase-containing plates for colony counts. Quantitative blood cul-
trast, neither methicillin nor flucloxacillin killed or inhibitedtures and spleen cultures were done in parallel. The numbers of
any of the isolates when used at peak concentrations achievablecolonies growing on the plates were determined after 48 h of
incubation at 357C. Bacterial densities in the vegetations were in human serum during iv therapy (i.e., 100 mg/L).
expressed as log10 colony-forming units per gram of tissue. The Determination of PBP 2A affinity. The drug concentrations
dilution technique permitted the detection of ⁄2 log10 cfu/g of inhibiting 50% and 90% of [3H]penicillin labeling of PBP 2A
vegetation. For statistical comparisons of differences between the were determined in membrane fractions of the penicillinase-
median vegetation bacterial densities of various treatment groups, negative strain COL0. The IC50 and IC90 of methicillin were
culture-negative vegetations were considered to contain 2 log10 350 and 4000 mg/L, respectively. In comparison, these values
cfu/g.
were ⁄40-fold lower for cefamandole and amoxicillin: 8 andStatistical analysis. Fisher’s exact test was used to compare
100 mg/L for cefamandole and 4 and 90 mg/L for amoxicillin.the rates of valvular infection. Bonferroni’s correction was used
These results were reproducible on repeating the experimentsfor multiple-group comparison. Median bacterial densities in the
several times with independent batches of cell membranes.vegetations of various treatment groups were compared by the
nonparametric Mann-Whitney Wilcoxon unpaired test or the Thus, the relatively good in vitro activity of cefamandole and
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Figure 1. Population analysis profile of penicil-
linase-negative and homogeneously methicillin-resis-
tant strain COL0 (A) and its penicillinase-producing
transformant COL/ (B). Various sizes of bacterial in-
ocula were spread on agar plates containing increasing
concentrations of either methicillin (j), cefamandole
(m), or amoxicillin (l). B also shows results with
amoxicillin-clavulanate (s) against penicillinase-pro-
ducing strain COL/. Points indicate no. of colonies
growing on plates after 48 h of incubation at 357C.
amoxicillin against MRSA correlated with a greater PBP 2A successfully cured valvular infections and was equivalent to
or better than control treatment with vancomycin. Therefore,affinity of these compounds compared with that of methicillin.
Treatment of experimental endocarditis due to penicillinase- continuous infusion of cefamandole was used in the next series
of experiments.negative MRSA. The homogeneously methicillin-resistant but
penicillinase-negative strain COL0 was tested in these experi- Treatment of experimental endocarditis due to penicillinase-
producing MRSA. A second series of experiments investi-ments. Two cefamandole regimens mimicking drug concentra-
tions achievable in the sera of humans were tested, one simulat- gated the impact of bacterial penicillinase production on the
outcome of cefamandole therapy in vivo. Both the penicil-ing standard 4 times daily administration of 3 g of cefamandole,
and one consisting of continuous infusion of the drug. Figure linase-negative and -positive versions of strains COL and P8
were tested in parallel. Figure 3 shows that continuous infusion2 depicts the serum kinetics of these cefamandole regimens
(figure 2A) and their therapeutic results after 3 days of treat- of cefamandole successfully treated animals infected with the
b-lactamase–negative organisms. However, although cefa-ment (figure 2B). Human-like kinetics produced by sequential
treatment failed to cure the animals, in spite of repeated high mandole was not affected by penicillinase in susceptibility tests
in vitro, the antibiotic was significantly less effective againstpeak serum levels of the drug (600 mg/L). Since cefamandole
had a short serum half-life, it was possible that transient antibi- the penicillinase-producing version of the strains in vivo. This
observation raised questions about the stability of cefamandoleotic peaks might not compensate for the prolonged periods of
drug levels below the MIC and that continuous drug infusion to penicillinase in this condition.
Penicillinase stability of cefamandole. One reason for themight perform better than sequential administration. Indeed,
figure 2 shows that continuous infusion producing steady serum discrepancy between in vitro and in vivo results might be re-
lated to an inoculum effect. As illustrated in figure 4, penicil-concentrations of cefamandole of 100 mg/L (dashed line)
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Figure 2. Kinetics of cefamandole in serum of rats
(A) and results of treatment of experimental endocar-
ditis due to penicillinase-negative strain COL0 (B).
A depicts cefamandole kinetics that either simulated
human pharmacokinetics produced by sequential ad-
ministration of 3 g of drug 4 times daily (CEF 3g
q.i.d.) or produced constant antibiotic levels of 100
mg/L (CEF continuous infusion). Dotted line in A
indicates MIC of cefamandole for test organism. In
B, treatment groups are indicated at tops of columns.
Each dot indicates bacterial density in vegetations of
single animal. Dashed lines indicate median value in
each treatment group. Statistical differences between
groups were determined by Kruskal-Wallis 1-way
analysis of variance on ranks. Differences in median
values among treatment groups were significant (P 
.001). Differences between specific groups, as deter-
mined by Dunn’s method, are indicated at bottom. NS
 not significant.
Figure 3. Treatment of experimental endocarditis
with cefamandole given in continuous infusion (pro-
ducing constant serum levels of 100 mg/L) in rats
infected with penicillinase-negative and penicillinase-
positive versions of strains COL and P8. Untreated
controls were all heavily infected and are not shown.
Each dot in columns indicates bacterial density in veg-
etation of single animal; dashed lines indicate median
value in each treatment group. Statistical differences
between pairs of groups were determined by Mann-
Whitney-Wilcoxon unpaired test and Fisher’s exact
test. Both tests gave concordant results. Therefore,
only highest P values given by either test are shown
at bottom.
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Figure 4. Model for inoculum-dependent degradation of b-lactams operating in infected vegetations (A) compared with situation in MIC
test tubes (B). Upper part of A illustrates bacterial clusters packed in infected vegetations, surrounded by large concentrations of penicillinase
(arrows). Graph in A shows in vitro degradation of amoxicillin (triangles), cefamandole (circles), and methicillin (squares) exposed to large
bacterial inocula of either strain COL/ (penicillinase-producer; closed symbols) or COL0 (penicillinase-negative; open symbols). B shows
results of similar experiments with lower inoculum sizes, to mimic situation in MIC test tubes. Model is similar to that proposed by Goldman
and Petersdorf [15].
linase concentrations might be higher around bacterial clusters this supports the possibility that large bacterial densities and
penicillinase concentrations in the vegetations might result inpacked in infected vegetations (figure 4A) than around single
organisms suspended in broth cultures or spread on agar plates significant degradation of cefamandole at the infected site. This
hypothesis was further tested by using the penicillinase inhibi-(figure 4B). Since cefamandole is not entirely immune to peni-
cillin-induced hydrolysis [21], degradation of cefamandole tor sulbactam in the next experiments.
Prevention of penicillinase-induced degradation of cefaman-might become an issue when switching from the in vitro sus-
ceptibility tests to deep-seated infections in vivo. A possible dole by sulbactam. If the above assumption is correct, then
combination of cefamandole with a penicillinase inhibitor, suchinoculum effect was investigated in vitro by testing the stability
of cefamandole and other antibiotics exposed to broth cultures as sulbactam, might restore its antibacterial efficacy. This was
tested both in vitro and in vivo. First, large concentrations ofcontaining various bacterial counts of either strain COL/ or
strain COL0. In the presence of large bacterial numbers (i.e., sulbactam (400 mg/L) successfully prevented degradation of
cefamandole in vitro, as tested by an assay similar to that108 –109 cfu/mL; figure 4A, graph), cefamandole and methicil-
lin lost almost 50% of their original activity within 3 h of presented in figure 4 that used the penicillinase-producing strain
COL/ as test bacterium. In a typical experiment, the residualexposure. Accordingly, amoxicillin barely resisted a few min-
utes in this experiment. In contrast, the three antibiotics were activity of cefamandole exposed alone to the culture was 76%
after 2 h of incubation and 0% after 4 h and 6 h of incubation.perfectly stable when exposed to broth cultures of the penicil-
linase-negative strain COL0. In the presence of lower bacterial In the presence of sulbactam, in comparison, the residual
activity of cefamandole was 100% at 2 h, 60% at 4 h, andnumbers (i.e., 105 –106 cfu/mL; figure 4B, graph), on the other
hand, both cefamandole and methicillin were quite stable for 33% at 6 h.
Second, combination of cefamandole with sulbactam in vivoup to 18 h, whereas amoxicillin was progressively degraded
over this time. Similar results were obtained when the pair of also restored the drug efficacy. Sulbactam administration pro-
duced a peak concentration in the serum of rats (mean { SDpenicillinase-producing and -nonproducing MRSA P8/ and
P80 were used instead of COL (data not shown). Therefore, of 3 animals) of 39.9 { 11.5 mg/L at 30 min, followed by
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concentrations of 30.8 { 1 mg/L at 1 h, 9.8 { 0.1 mg/L at
2 h, and undetectable values at 6 h. Figure 5 indicates that
administration of sulbactam at this dose 4 times a day reestab-
lished the therapeutic efficacy of continuous infusion of cefa-
mandole, as if it were used against the penicillinase-negative
version of the organism (see figure 3). Thus, taken together,
these experiments strongly argue in favor of a direct role of
in situ production of penicillinase as a cause of cefamandole
treatment failure against experimental endocarditis due to peni-
cillinase-producing MRSA.
Prophylaxis of experimental endocarditis. Although cefa-
mandole was ineffective against experimental endocarditis due
to penicillinase-producing MRSA, it might be successful for
prophylaxis of such infection. Indeed, prophylaxis more closely
resembles the test tube situation than does established infection,
Figure 6. Cefamandole prophylaxis of experimental endocarditisbecause prophylactic drugs are given while bacteria are circu-
due to penicillinase-producing strain COL/. Prophylaxis regimens are
lating in the blood and only beginning to colonize the cardiac indicated. No. of animals in each group are shown at bottom.
lesions [22, 23]. Figure 6 shows that cefamandole successfully
prevented endocarditis due to the penicillinase-producing strain
COL/, whether it was administered sequentially as in humans
centration of penicillinase around the bacteria might be a criti-or in continuous infusion, producing constant serum levels of
cal factor determining antibiotic efficacy.
drug of 100 mg/L. Vancomycin prophylaxis was also effective,
whereas flucloxacillin completely failed to prevent infection.
These results further support the hypothesis that the local con- Discussion
The present studies highlight two pharmacodynamic limita-
tions of cefamandole in the treatment of experimental endocar-
ditis: one relatively trivial, which relates to the antibiotic dosing
regimen, and a second, more fundamental, that points to the
essential role of penicillinase in b-lactam resistance of MRSA.
First, treatment of experimental endocarditis due to penicil-
linase-negative MRSA could not be achieved by sequential
drug administration, because repeated transient peaks of cefa-
mandole in the serum were unable to ensure prolonged supra-
MIC drug concentrations in vivo. It is well established that
b-lactam drugs must be maintained above growth-inhibiting
concentrations to be effective [24, 25], and this limitation was
easily overcome by using continuous infusion of the drug.
Second, treatment of endocarditis due to penicillinase-posi-
tive MRSA could not be achieved even by continuous drug
infusion, presumably because cefamandole was inactivated in
situ by bacterial penicillinase produced in the vegetations. This
limitation was not expected, because large doses of the rela-
Figure 5. Treatment of experimental endocarditis with cefaman- tively penicillinase-stable cefamandole were assumed to over-
dole given to rats in continuous infusion (producing constant serum come penicillinase-induced hydrolysis in vivo. However, com-
levels of 100 mg/L) either alone (CEF) or in combination with sulbac- plementary experiments clearly demonstrated an inoculum-
tam (CEF / SUL) at doses simulating human pharmacokinetics pro-
dependent degradation of cefamandole by penicillinase, whichduced by administration of 1 g of drug 4 times a day. Rats were
could be prevented by coadministration of a penicillinase inhib-infected with penicillinase-producing, homogeneous methicillin-resis-
tant strain COL/. Each dot indicates bacterial density in vegetation itor such as sulbactam. This supports the possibility that large
of single animal. Dashed lines indicate median value in each treatment amounts of the enzyme surrounding bacterial clusters in the
group. Statistical differences between groups were determined by vegetations could protect the microorganisms from the drug
Kruskal-Wallis 1-way analysis of variance on ranks (P  .014) with
and confirms a previous hypothesis by Goldman and Petersdorfpairwise comparison between specific groups by Dunn’s method and
[15], who postulated that the poor activity of cefazolin againstFisher’s exact test with Bonferroni’s correction. Both tests gave con-
cordant results. NS  not significant. experimental endocarditis due to a penicillinase-producing
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strain of S. aureus could be due to degradation of the drug at enzyme are crucial for the survival of the organisms. On the
side of the antibiotic, slow diffusion into the vegetation, strongthe infected site. Moreover, it was further supported by the fact
that any of the cefamandole regimens that failed in therapeutic penicillinase-inducing capacity, and low penicillinase stability
are playing against the drug. Some of these characteristics canexperiments were highly effective in the prophylaxis studies,
a setting more closely resembling the test tube than does the be defined, at least on the antibiotic side. However, the interplay
of these factors in vivo may be difficult to predict. The repro-vegetation situation (see figure 4). Therefore, while the slow
inactivation of cefamandole by penicillinase did not affect the ducible therapeutic success of certain b-lactams against penicil-
linase-negative MRSA, on the other hand, supports the factresults of in vitro susceptibility tests, it was clearly responsible
for treatment failure in vivo. that PBP 2A can be blocked in vivo. Nevertheless, b-lactams
with improved PBP 2A affinity would certainly gain in anti-The observation is important because it underlines the fact
that in vitro susceptibility tests might not be predictive of in MRSA efficacy and act in conjunction with their stability to
penicillinase against these organisms. Therefore, both bettervivo results. Moreover, the lack of cefamandole efficacy against
penicillinase-producing strains also highlights the everlasting PBP 2A affinity and penicillinase stability are important in the
development of future b-lactams active against MRSA.role of penicillinase in b-lactam resistance of staphylococci.
Besides MRSA, penicillinase may also adversely affect the Taken together, the present observations show that while
cefamandole demonstrates both relatively good PBP 2A affinityefficacy of anti-staphylococcal b-lactams against methicillin-
susceptible S. aureus. For example, combination of cefopera- and anti-MRSA activity in vitro, it may fail against MRSA
infections in vivo because of production of bacterial penicil-zone with sulbactam was more effective than cefoperazone
alone against experimental endocarditis due to methicillin-sus- linase. This is in contradiction to a report suggesting that cefa-
mandole might be effective for treatment of soft tissue infec-ceptible S. aureus in rabbits, presumably because sulbactam
protected cefoperazone from penicillinase-induced degradation tions due to MRSA in humans [11] and raises caution
concerning this indication. On the other hand, however, 1-[26]. Another example is borderline methicillin-resistant S.
aureus, which have increased methicillin MICs because of pen- day prophylaxis with cefamandole could effectively prevent
experimental MRSA endocarditis, presumably because individ-icillinase overproduction [27]. Although these organisms are
not clinically relevant, they were able to decrease the efficacy ual production of penicillinase by circulating bacteria is low.
Cefamandole was known to be effective for prophylaxis inof ampicillin-sulbactam treatment of experimental endocarditis
due to borderline methicillin-resistant S. aureus in rats [28]. cardiovascular surgery before the methicillin resistance era [31,
32]. It might now be considered for prophylaxis against MRSATherefore, production of penicillinase is not harmless, even
when supposedly penicillinase-stable drugs are used to treat and methicillin-resistant S. epidermidis as well, especially
when the use of vancomycin is prohibited to avoid the selectionmethicillin-susceptible S. aureus.
In the case of MRSA, penicillinase may represent a primary of vancomycin-resistant enterococci. Additional studies are
warranted to further assess this prophylactic efficacy.restriction to the possible use of existing b-lactams against
infections due to such bacteria. Indeed, several studies have
validated the fact that b-lactams with a relatively good PBP 2A
Acknowledgmentsaffinity, such as penicillin, ampicillin, and amoxicillin, could
successfully treat experimental MRSA infections, provided that
We thank Marlyse Giddey, Jacques Vouillamoz, and Oscar Mar-
they could escape penicillinase-induced degradation [5–9]. chetti for outstanding technical assistance.
These observations were recently extended to methicillin-resis-
tant Staphylococcus epidermidis, which also produce PBP 2A
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